This review provides a systematic mechanistic analysis of biologic treatment strategies for severe asthma, particularly offering significant guidance on precision intervention approaches targeting IL-4Rα and TSLP, which can help optimize clinical trial design and patient stratification strategies.
Literature Overview
The article 'Current and Emerging Biologic Therapies for Severe Asthma', published in the journal Drugs, systematically explores the mechanisms of action, clinical efficacy, and future directions of currently approved and investigational biologics for the treatment of severe asthma. The article reviews therapeutic advances targeting key pathways such as IgE, IL-5, IL-4Rα, and TSLP, and provides an in-depth analysis of the limitations of existing therapies in T2-low and mixed phenotypes. It further highlights that emerging therapies are focusing on upstream alarmins such as TSLP and IL-33, as well as multi-target inhibition strategies, aiming to achieve broader anti-inflammatory effects and disease-modifying outcomes.Background Knowledge
Severe asthma (SA) is a heterogeneous disease characterized by persistent symptoms, frequent exacerbations, and dependence on oral corticosteroids (OCS), despite treatment with high-dose inhaled corticosteroids (ICS) and long-acting β2-agonists (LABA). Approximately 3.6–10% of asthma patients fall into this category, yet they bear a disproportionately high healthcare burden. The current therapeutic bottleneck lies in the fact that existing biologics primarily target T2-high phenotypes—such as anti-IgE, anti-IL-5, and anti-IL-4Rα therapies—and show limited efficacy in T2-low or neutrophilic asthma. Moreover, even among T2-high patients, a subset responds poorly to single-pathway inhibition, suggesting unresolved inflammatory mechanisms, such as persistent activation of epithelial-derived alarmins including TSLP, IL-33, and IL-25. This review focuses on overcoming the limitations of 'single-pathway' targeted therapies by exploring upstream regulation and multi-target synergistic interventions to cover a broader spectrum of inflammatory endotypes, particularly addressing unmet needs such as OCS dependence and airway remodeling. The study emphasizes the central role of biomarkers such as FeNO, blood eosinophil count (BEC), and IgE in guiding treatment selection, while also highlighting the complexity of IL-17A, TNF-α, and neutrophilic inflammation in T2-low asthma, indicating the need for more refined phenotyping strategies.
Research Methods and Experiments
The authors conducted a systematic review of phase III clinical trial data, real-world evidence, and mechanistic studies of the seven currently approved biologics—including omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, and tezepelumab—to integrate and analyze their efficacy across different asthma phenotypes. Key evidence from multiple randomized controlled trials (e.g., QUEST, ZONDA, NAVIGATOR) shows that dupilumab outperforms other monoclonal antibodies in reducing exacerbation rates, improving lung function (FEV1), and enabling OCS tapering, particularly in eosinophilic phenotypes. Tezepelumab, the first drug targeting TSLP, also demonstrates efficacy in T2-low patients, suggesting that upstream intervention may transcend traditional T2 classification boundaries. Additionally, the study cites data from the SWIFT-1 and SWIFT-2 trials, confirming that the long-acting anti-IL-5 agent depemokimab can be administered once every six months, significantly reducing exacerbation rates while maintaining BEC suppression, thus demonstrating the clinical value of pharmacokinetic optimization.Key Conclusions and Perspectives
Research Significance and Prospects
This study provides clear direction for drug development: shifting from single-cytokine inhibition toward upstream regulation and multi-pathway synergistic intervention. For example, targeting TSLP or IL-33 may enable 'upstream blockade,' reducing downstream inflammatory cascade amplification and offering disease-modifying potential. Furthermore, Fc optimization and bispecific designs will enhance drug exposure and target coverage, particularly beneficial for patients with atypical or mixed inflammatory phenotypes.
In terms of clinical monitoring, the study emphasizes that combining FeNO, BEC, and IgE can optimize biologic selection; in the future, integrating multi-omics data to build predictive models will enable truly personalized therapy. For disease modeling, there is a need to develop animal models that recapitulate T2-low and mixed phenotypes—such as IL-17A transgenic or neutrophilic inflammation models—to validate novel therapeutic targets.
Conclusion
This review systematically outlines the current status and future directions of biologic therapies for severe asthma, emphasizing a paradigm shift from 'phenotype matching' to 'mechanism-driven' treatment. While the seven currently approved biologics have significantly improved outcomes for T2-high patients, unmet needs remain in T2-low, mixed phenotypes, and OCS-dependent cases. Emerging strategies—such as targeting TSLP and IL-33 or developing multispecific antibodies—hold promise for overcoming current therapeutic limitations, enabling broader anti-inflammatory effects and potential disease modification. From bench to bedside, this study provides a theoretical framework for developing next-generation precision therapies: by integrating biomarkers, optimizing drug design (e.g., Fc engineering, long-acting formulations), and exploring upstream targets, we can advance severe asthma management from symptom control toward disease modification. Future research should focus on identifying response-predictive biomarkers, validating the real-world efficacy of novel targets, and leveraging advanced animal models (e.g., humanized or gene-edited models) to accelerate translation, ultimately improving long-term quality of life and treatment accessibility for patients with severe asthma.
